Xeris Pharmaceuticals, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$5.2Mgeneral payments (2019-2025)
$1,650research payments (2019-2025)
37,653clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2020 $191K
2021 $544K
2022 $746K
2023 $1.1M
2024 $1.1M
2025 $1.5M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Endocrinology, Diabetes & Metabolism $2.1M
Family $506K
Family Medicine $443K
Internal Medicine $442K
Nurse Practitioner $361K
Infectious Disease $359K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Jeffrey Sherman Deerfield, IL Infectious Disease $357,263.25
Jessica Adkins Savannah, GA Nurse Practitioner $177,139.85
Elena Christofides Columbus, OH Endocrinology, Diabetes & Metabolism $156,526.81
Philip Rabito New York, NY $118,746.18
Bruce Bode Atlanta, GA Endocrinology, Diabetes & Metabolism $89,526.92
Ilja Hulinsky Bridgeport, CT Endocrinology, Diabetes & Metabolism $81,376.63
Bantwal Baliga Columbus, GA Family Medicine $71,960.14
Michael Shanik Smithtown, NY Endocrinology, Diabetes & Metabolism $50,482.48
John Paes Westerville, OH Endocrinology, Diabetes & Metabolism $48,543.77
Firas Akhrass San Antonio, TX Endocrinology, Diabetes & Metabolism $44,234.83

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.